Cargando…

Mutation analysis and clinical characterization of Iranian patients with mucopolysaccharidosis type I

BACKGROUND: Mucopolysaccharidosis type I (MPSI) is a rare autosomal recessive disorder caused by a deficiency of α‐l‐iduronidase (IDUA) encoded by the IDUA gene. We examined the mutation spectrum of the IDUA gene to explain the clinical, biochemical, and molecular features in 21 Iranian patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Taghikhani, Mohammad, Khatami, Shohreh, Abdi, Mohammad, Hakhamaneshi, Mohammad Said, Alaei, Mohammad Reza, Zamanfar, Daniel, Vakili, Rahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805319/
https://www.ncbi.nlm.nih.gov/pubmed/31386236
http://dx.doi.org/10.1002/jcla.22963
_version_ 1783461354472996864
author Taghikhani, Mohammad
Khatami, Shohreh
Abdi, Mohammad
Hakhamaneshi, Mohammad Said
Alaei, Mohammad Reza
Zamanfar, Daniel
Vakili, Rahim
author_facet Taghikhani, Mohammad
Khatami, Shohreh
Abdi, Mohammad
Hakhamaneshi, Mohammad Said
Alaei, Mohammad Reza
Zamanfar, Daniel
Vakili, Rahim
author_sort Taghikhani, Mohammad
collection PubMed
description BACKGROUND: Mucopolysaccharidosis type I (MPSI) is a rare autosomal recessive disorder caused by a deficiency of α‐l‐iduronidase (IDUA) encoded by the IDUA gene. We examined the mutation spectrum of the IDUA gene to explain the clinical, biochemical, and molecular features in 21 Iranian patients with MPSI. METHODS: Sanger sequencing was used to measure the IDUA gene sequence in the coding region and exon‐intron boundaries. We recorded the clinical findings of studied patients at the first diagnosis of disease and then during the treatment and follow‐up. RESULTS: Five different missense disease‐causing mutations were determined in our patient groups, indicating 90.48% of detection rate. The most widespread mutation was the p.Y109H, occurring in 15.625% of all alleles, which was reported for the first time in our study. Other frequent mutations were as follows: p.Ser157Pro (12.5%), p.Gly84Arg (12.5%), p.Asp257His (9.375%), and p.Asp301Glu (9.375%). Three ones of them were new missense mutations: p.Ser157Pro, p.Asp257His, and p.Asp301Glu. DISCUSSION: The results of this study explain the different spectrum of IDUA gene mutations in our patients with MPSI. We introduced here 32 different variants including four new variants: p.Y109H (15.625%), p.S157P (12.5%), p.D257H (9.375%), and p.D301E (9.375%). In this series, there was no relationship between the happening of clinical features and genotype variations and biochemical findings.
format Online
Article
Text
id pubmed-6805319
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68053192019-11-12 Mutation analysis and clinical characterization of Iranian patients with mucopolysaccharidosis type I Taghikhani, Mohammad Khatami, Shohreh Abdi, Mohammad Hakhamaneshi, Mohammad Said Alaei, Mohammad Reza Zamanfar, Daniel Vakili, Rahim J Clin Lab Anal Research Articles BACKGROUND: Mucopolysaccharidosis type I (MPSI) is a rare autosomal recessive disorder caused by a deficiency of α‐l‐iduronidase (IDUA) encoded by the IDUA gene. We examined the mutation spectrum of the IDUA gene to explain the clinical, biochemical, and molecular features in 21 Iranian patients with MPSI. METHODS: Sanger sequencing was used to measure the IDUA gene sequence in the coding region and exon‐intron boundaries. We recorded the clinical findings of studied patients at the first diagnosis of disease and then during the treatment and follow‐up. RESULTS: Five different missense disease‐causing mutations were determined in our patient groups, indicating 90.48% of detection rate. The most widespread mutation was the p.Y109H, occurring in 15.625% of all alleles, which was reported for the first time in our study. Other frequent mutations were as follows: p.Ser157Pro (12.5%), p.Gly84Arg (12.5%), p.Asp257His (9.375%), and p.Asp301Glu (9.375%). Three ones of them were new missense mutations: p.Ser157Pro, p.Asp257His, and p.Asp301Glu. DISCUSSION: The results of this study explain the different spectrum of IDUA gene mutations in our patients with MPSI. We introduced here 32 different variants including four new variants: p.Y109H (15.625%), p.S157P (12.5%), p.D257H (9.375%), and p.D301E (9.375%). In this series, there was no relationship between the happening of clinical features and genotype variations and biochemical findings. John Wiley and Sons Inc. 2019-08-06 /pmc/articles/PMC6805319/ /pubmed/31386236 http://dx.doi.org/10.1002/jcla.22963 Text en © 2019 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Taghikhani, Mohammad
Khatami, Shohreh
Abdi, Mohammad
Hakhamaneshi, Mohammad Said
Alaei, Mohammad Reza
Zamanfar, Daniel
Vakili, Rahim
Mutation analysis and clinical characterization of Iranian patients with mucopolysaccharidosis type I
title Mutation analysis and clinical characterization of Iranian patients with mucopolysaccharidosis type I
title_full Mutation analysis and clinical characterization of Iranian patients with mucopolysaccharidosis type I
title_fullStr Mutation analysis and clinical characterization of Iranian patients with mucopolysaccharidosis type I
title_full_unstemmed Mutation analysis and clinical characterization of Iranian patients with mucopolysaccharidosis type I
title_short Mutation analysis and clinical characterization of Iranian patients with mucopolysaccharidosis type I
title_sort mutation analysis and clinical characterization of iranian patients with mucopolysaccharidosis type i
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805319/
https://www.ncbi.nlm.nih.gov/pubmed/31386236
http://dx.doi.org/10.1002/jcla.22963
work_keys_str_mv AT taghikhanimohammad mutationanalysisandclinicalcharacterizationofiranianpatientswithmucopolysaccharidosistypei
AT khatamishohreh mutationanalysisandclinicalcharacterizationofiranianpatientswithmucopolysaccharidosistypei
AT abdimohammad mutationanalysisandclinicalcharacterizationofiranianpatientswithmucopolysaccharidosistypei
AT hakhamaneshimohammadsaid mutationanalysisandclinicalcharacterizationofiranianpatientswithmucopolysaccharidosistypei
AT alaeimohammadreza mutationanalysisandclinicalcharacterizationofiranianpatientswithmucopolysaccharidosistypei
AT zamanfardaniel mutationanalysisandclinicalcharacterizationofiranianpatientswithmucopolysaccharidosistypei
AT vakilirahim mutationanalysisandclinicalcharacterizationofiranianpatientswithmucopolysaccharidosistypei